Eur J Neurol. 2009;16(6):662–73.PubMedCrossRef 51. Jha AK, Wright SM, Perlin JB. Performance measures, vaccinations, and pneumonia rates among high-risk patients in Veterans Administration health care. Am J Public Health. 2007;97(12):2167–72.PubMedCentralPubMedCrossRef 52. Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003. Clin Infect Dis. 2006;43(2):141–50.PubMedCrossRef

53. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass Repotrectinib mw M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: CBL0137 price opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729–35.PubMedCrossRef 54. Centers for Disease C, Prevention. Noninfluenza vaccination coverage among adults—United States, 2011. Morb Mortal Wkly Rep. 2013;62(4):66–72. 55. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen

Intern Med. 1999;14(9):555–8.PubMedCentralPubMedCrossRef 56. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008;27(3):274–82.PubMedCrossRef 57. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran’s affairs hospital discharge databases

coded serious bacterial infections accurately. J Clin Epidemiol. 2007;60(4):397–409.PubMedCrossRef 58. Abraham NS, Cohen DC, Rivers B, Richardson P. Validation of administrative data used for the diagnosis of upper gastrointestinal events following Carnitine dehydrogenase nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther. 2006;24(2):299–306.PubMedCrossRef”
“Introduction Staphylococcus aureus continues to be a major healthcare threat. Methicillin-resistant S. aureus (MRSA) demonstrating reduced susceptibility to glycopeptides and lipopeptides such as vancomycin (VAN), teicoplanin (TEI), and daptomycin (DAP) severely limits our therapeutic Navitoclax options for treating complicated infections due to this pathogen. MRSA now comprises 55.5% of hospital-acquired S. aureus infections [1, 2]. MRSA with reduced susceptibility to glyco- and lipopeptide antibiotics is increasingly being reported. Infections caused by MRSA isolates with reduced VAN susceptibility often lead to worse clinical outcomes, especially in strains identified as VAN-intermediate S. aureus (VISA), heterogeneous VISA (hVISA), or DAP non-susceptible (DNS) [3–10]. However, relatively few new antimicrobial agents are available, necessitating alternative treatment strategies including combination therapies and dose optimization as well as maximization of older antimicrobials.